The Conversio program has proven effective at increasing compliance with prescribed medication regimens, improving patient education and creating a patient experience that benefits from a tailored approach to therapy; one that evolves in accordance with the progression of the patient’s condition. Through its comprehensive pharmacotherapy management Conversio has been able to work successfully with health plan partners in bending the cost curve for ED and hospitalization expense.
As depicted in Figure 1, the Conversio program provided for a marked reduction in total PMPM expenditures for a client’s Medicare population. The study compared total PMPM costs for ED, Respiratory Hospital and Pharmacy expense for a one-year period prior to enrollment in the program to the ongoing expense following the first patient fill for a two-year period thereafter.
A separate client led study focused on the impact of the Conversio program in reducing 30 and 90-day respiratory readmissions. Program readmission rates were compared against the Medicare average and that of a set of high risk individuals identified by the plan prior to program intervention. As depicted in Figure 2, the Conversio program significantly outperformed the Medicare Average and resulted in a 58% reduction in 30-day readmissions for the high-risk cohort previously managed solely with health plan resources.